--- title: "EXOZYMES INC. (EXOZ) stock: news and investor profile" url: "https://aibio.space/companies/exozymes/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "EXOZYMES INC. (NASDAQ: EXOZ), United States. Listing facts, related biotech companies and news on aibio.space." --- EXOZ EXOZYMES INC. NASDAQ · United States # EXOZYMES INC. (EXOZ) news EXOZYMES INC. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EXOZ, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. ## Latest EXOZYMES INC. news We have not published a story on EXOZYMES INC. yet. When there is news, it will appear here. ## EXOZYMES INC. at a glance - **Ticker**: EXOZ - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $5.7 million ### Related companies - [FAMILY OFFICE OF AMERICA, INC.](https://aibio.space/companies/family-office-of-america/) OTC: FOFA - [REVVITY, INC.](https://aibio.space/companies/revvity/) NYSE: RVTY - [TANDEM DIABETES CARE INC](https://aibio.space/companies/tandem-diabetes-care/) NASDAQ: TNDM - [RadNet](https://aibio.space/companies/radnet/) NASDAQ: RDNT - [AGILENT TECHNOLOGIES, INC.](https://aibio.space/companies/agilent-technologies/) NYSE: A - [Beyond Air](https://aibio.space/companies/beyond-air/) NASDAQ: XAIR - [Neuronetics](https://aibio.space/companies/neuronetics/) NASDAQ: STIM - [BIOFORCE NANOSCIENCES HOLDINGS, INC.](https://aibio.space/companies/bioforce-nanosciences/) OTC: BFNH ### Also on NASDAQ - [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) ABUS - [PRECISION OPTICS CORPORATION, INC.](https://aibio.space/companies/precision-optics/) POCI - [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) SKYE - [Filana Therapeutics](https://aibio.space/companies/filana-therapeutics/) FLNA - [Aptevo Therapeutics](https://aibio.space/companies/aptevo-therapeutics/) APVO - [Scilex Holding](https://aibio.space/companies/scilex/) SCLX ## EXOZYMES INC. annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$3.7 million](https://www.sec.gov/Archives/edgar/data/2010788/000149315226013563/) | [$1.9 million](https://www.sec.gov/Archives/edgar/data/2010788/000149315226013563/) | | Net income (loss) | [-$9.2 million](https://www.sec.gov/Archives/edgar/data/2010788/000149315226013563/) | [-$5.9 million](https://www.sec.gov/Archives/edgar/data/2010788/000149315226013563/) | | Cash from operations | [-$6.5 million](https://www.sec.gov/Archives/edgar/data/2010788/000149315226013563/) | [-$8.5 million](https://www.sec.gov/Archives/edgar/data/2010788/000149315226013563/) | | Cash and equivalents | [$3.0 million](https://www.sec.gov/Archives/edgar/data/2010788/000149315226037725/) | [$9.7 million](https://www.sec.gov/Archives/edgar/data/2010788/000149315226013563/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about EXOZYMES INC. What is the ticker symbol of EXOZYMES INC.? EXOZYMES INC. trades under the ticker EXOZ on NASDAQ. Where is EXOZYMES INC. listed? EXOZYMES INC. is listed on NASDAQ. Which country or territory is EXOZYMES INC. listed under? Our directory records EXOZYMES INC. under United States. Does aibio.space cover EXOZYMES INC.? aibio.space lists EXOZYMES INC. among 2,820 public biotech companies and publishes its news here as stories appear. Is EXOZYMES INC. profitable? EXOZYMES INC. reported a net loss of $9.2 million for the fiscal year ended Dec 31, 2025, and used $6.5 million of cash in operations, per its annual report to the SEC. How much does EXOZYMES INC. spend on research and development? $3.7 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does EXOZYMES INC. have? $5.7 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: EXOZYMES INC. Members talk about EXOZYMES INC. (EXOZ). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at EXOZYMES INC., newest first. Each line links the filing it comes from. 1. 2026-06-17 Financings Reported a financing. SEC Form 8-K (Items 1.01,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/2010788/000149315226029119/ex99-1.htm) 2. 2026-05-29 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/2010788/000149315226025698/form424b5.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:EXOZ on TradingView](https://www.tradingview.com/symbols/NASDAQ-EXOZ/). ## Listing details EXOZYMES INC. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EXOZ, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: EXOZYMES INC. - **Ticker**: EXOZ - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/exozymes/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "EXOZYMES INC. (EXOZ) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/exozymes/